Tigermed
Tigermed
Tigermed is a contract research company providing whole process clinical trial services for the R&D of pharmaceuticals.
Tigermed, founded in December, 2014 and headquartered in Hangzhou, is a contract research organization (CRO) focused on providing professional services for the entire process of clinical trials for new drug research. The founder is Ye Xiaoping. Listed on the SZSE on August 17, 2012, the company's major shareholders are Ye Xiaoping, Hong Kong Securities Clearing Co., Ltd and Cao Xiaochun. Rivals that have direct and indirect competition with Tigermed include Kintor, HitGen, Aprea Therapeutics, BridgeBio Pharma, etc.
- All
- News
- Analysis
- Research
In-depth
Briefing Jun 13, 2022 09:44 AM
· Healthcare
Cro plate fell, and Wuxi apptec fell nearly 10%
Research
Healthcare, Technology, Consumer StaplesWIA2020 | Rising Tech Stars 2020: Global & China's 100
Dec 09, 2020 09:57 AM
Dec 09, 2020 09:39 AM
Research
Real Estate, Consumer Discretionary, IndustrialsTech for Global, Globalization Footprints of the Established and the New
May 29, 2020 08:30 PM
Research
Real Estate, Consumer Discretionary, IndustrialsLow-Carbon Industry Expansion - Key Studies From Chinese Companies
May 28, 2020 12:40 PM
Briefing Feb 21, 2022 10:29 AM
· Healthcare
Baidu responded that it was unable to search "referee document network": caused by misoperation of the technical team
In-depth
Healthcare
BeiGene: a Vast Opportunity Lies Ahead – But We Remain Cautious
BeiGene, a leader in China's novel pharmaceutical industry, recently received approval in Kuwait, Bahrain, and Qatar for its medication BRUKINSA (zanubrutinib). Previous contracts with major biopharma have produced substantial licensing income, but they did not lessen BeiGene's financial burden.
Jun 24, 2022 12:13 PM
Healthcare
RNA Biotech Therorna Bags Over CNY 280 Mn in Series A Financing Round
Therorna, specialized in the development of cutting-edge circular RNA technology-based vaccines and therapies, will accelerate the development of a new broad-spectrum COVID-19 vaccine and other product pipelines with the fresh proceeds.
Jun 23, 2022 03:45 PM
In-depth
Healthcare
WuXi AppTec: A Favorable Chinese Stock for MSCI and FTSE Russell
According to the latest quarterly index review, a Wuxi-based CRO company will be incorporated into the FTSE China A 50 Share Index. It has been considered a top holding by many MSCI China indexes for some time.
Jun 08, 2020 09:51 AM
Briefing Oct 19, 2021 10:11 AM
· Healthcare
Cro stocks rose in early trading
See more
Related Companies
EqualOcean is an information service provider and investment research company that aims to become a global platform for industrial innovation. Founded in February 2014 and headquartered in Beijing, with a client network covering over 50 countries, the firm provides comprehensive professional services, including industry research, investment analysis, innovation consulting, data products, corporate branding and international strategy.